Skip to main content

Tokyo, Published date 1 February, 2022

Advanced Medical Center Begins Treatment with Hitachi’s First Compact Proton Therapy System

Select category Corporate News

Shonan Kamakura Advanced Medical Center Begins Treatment with Hitachi's First Dedicated Compact Proton Therapy System

Proton Therapy System

Tokyo, February 1, 2022 --- Hitachi, Ltd. (TSE: 6501, ”Hitachi”) today announced that “Shonan Kamakura Advanced Medical Center” at Shonan Kamakura General Hospital of Tokushukai Medical Group, where Hitachi's compact proton therapy system (hereafter, “the system”) has been installed, has commenced treatment with the system on 31 January 2022. This is the first order for Hitachi’s dedicated compact proton therapy system.

Shonan Kamakura Advanced Medical Center is a medical facility providing comprehensive cancer treatment, including advanced radiotherapy, built adjacent to the site of Shonan Kamakura General Hospital by Tokushukai Group Medical Corporation, which operates approximately 400 medical facilities and nursing homes throughout Japan. Until now, there have been no proton therapy facilities in Kanagawa Prefecture, where the center is located, but the compact proton therapy system, with its reduced footprint, makes it possible to install a proton therapy facility on a limited site close to the city center.



In response to the growing worldwide demand for smaller proton therapy systems, Hitachi has developed the proton therapy system, which is specifically designed for a single treatment room. The system is a compact proton therapy system which, by optimizing the layout of the machine, reduces the installation area to about 70% of that of conventional solutions, making it possible to install the system on a limited site in an urban area and reducing the cost and time involved in its installation. It is equipped with advanced technologies such as spot scanning irradiation technology, which allows the proton beam to be delivered according to the shape of the cancer, a 360° rotating gantry with cone-beam CT*1 for high-precision positioning, and Real-time image Gated Proton Therapy (RGPT)*2, making it both compact and highly functional.

Hitachi is committed to accelerating the global development of particle therapy system and contributing to cancer treatment around the world, as well as to further expanding its healthcare services.

*1 Cone beam CT provides three-dimensional anatomical images of patients, at isocenter immediately prior to being treated. Information on the location of bone is obtained from traditional orthogonal x-rays and the motion of tumors is captured by RGPT. These are then combined with the ability to identify healthy tissue surrounding a tumor, particularly the location and shape of soft tissue, via Cone beam CT.

*2 RGPT allows real-time beam irradiation to the tumor while compensating for movement associated with respiration. This technology was collaboratively developed between Hokkaido University and Hitachi, and supported by the Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST) of the Japan Society for the Promotion of Science.

Overview of Particle Therapy

Particle Therapy is an advanced type of cancer radiotherapy. Protons extracted from hydrogen atoms, or carbon ions are accelerated up to 70% of the speed of light. This energy is concentrated directly on the tumor while minimizing radiation dose to surrounding healthy tissue. Particle therapy improves the quality of life for cancer patients since the patient experiences no pain during treatment and the procedure has very few side effects compared to that of traditional radiotherapy. In most cases, patients can continue with their normal daily activities while undergoing treatment.

Website of Hitachi’s Particle Therapy System

https://www.hitachi.com/businesses/healthcare/products-support/pbt/

31 January 2024
Hitachi to Strengthen Business Structure to Achieve Sustainable Growth
Read more Select category Corporate News
31 January 2024
Hitachi Announces Consolidated Financial Results for the Third Quarter Ended December 31, 2023
Read more Select category Corporate News Finance